This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008 Mar 27;358(13):1409-11.

doi: 10.1056/NEJMc0801440.

HER2 status and benefit from adjuvant trastuzumab in breast cancer

Soonmyung Paik, Chungyeul Kim, Norman Wolmark

PMID: 18367751
DOI: 10.1056/NEJMc0801440

HER2 status and benefit from adjuvant trastuzumab in breast cancer

Soonmyung Paik et al. N Engl J Med. 2008.

. 2008 Mar 27;358(13):1409-11.

doi: 10.1056/NEJMc0801440.

Authors

Soonmyung Paik, Chungyeul Kim, Norman Wolmark

PMID: 18367751
DOI: 10.1056/NEJMc0801440

No abstract available

PubMed Disclaimer

Similar articles

Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S, Pickering L, Ellis P. Chowdhury S, et al. J Br Menopause Soc. 2006 Dec;12(4):172-4. doi: 10.1258/136218006779160517. J Br Menopause Soc. 2006. PMID: 17178019 Review.
Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Seidman AD. Seidman AD. Nat Clin Pract Oncol. 2006 Apr;3(4):178-9. doi: 10.1038/ncponc0460. Nat Clin Pract Oncol. 2006. PMID: 16596138 Clinical Trial. No abstract available.
Trastuzumab in the treatment of breast cancer.
Hortobagyi GN. Hortobagyi GN. N Engl J Med. 2005 Oct 20;353(16):1734-6. doi: 10.1056/NEJMe058196. N Engl J Med. 2005. PMID: 16236745 No abstract available.
Adjuvant trastuzumab for HER2-positive early breast cancer.
Palmieri FM, Myatt CV, Perez EA. Palmieri FM, et al. Clin J Oncol Nurs. 2010 Jun;14(3):326-36. doi: 10.1188/10.CJON.326-336. Clin J Oncol Nurs. 2010. PMID: 20529794 Review.
Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.
Kell MR, Power CP. Kell MR, et al. BMJ. 2005 Nov 19;331(7526):1202. doi: 10.1136/bmj.331.7526.1202. BMJ. 2005. PMID: 16293849 Free PMC article. No abstract available.

See all similar articles

Cited by

Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.
Chervo MF, Cordo Russo RI, Petrillo E, Izzo F, De Martino M, Bellora N, Cenciarini ME, Chiauzzi VA, Santa María de la Parra L, Pereyra MG, Güttlein LN, Podhajcer OL, Daniotti JL, Dupont A, Barchuk S, Figurelli S, Lopez Della Vecchia D, Roa JC, Guzmán P, Proietti CJ, Schillaci R, Elizalde PV. Chervo MF, et al. Oncogene. 2020 Sep;39(39):6245-6262. doi: 10.1038/s41388-020-01430-9. Epub 2020 Aug 25. Oncogene. 2020. PMID: 32843720
Chaperone-assisted E3 ligase CHIP: A double agent in cancer.
Kumar S, Basu M, Ghosh MK. Kumar S, et al. Genes Dis. 2021 Sep 1;9(6):1521-1555. doi: 10.1016/j.gendis.2021.08.003. eCollection 2022 Nov. Genes Dis. 2021. PMID: 36157498 Free PMC article. Review.
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study.
Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, Adamson DJ, Dewar JA, Thompson AM. Purdie CA, et al. Br J Cancer. 2010 Aug 10;103(4):475-81. doi: 10.1038/sj.bjc.6605799. Epub 2010 Jul 27. Br J Cancer. 2010. PMID: 20664587 Free PMC article.
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S, Sun SQ, Huang KL, Oh C, Bailey MH, Varghese R, Wyczalkowski MA, Ning J, Tripathi P, McMichael JF, Johnson KJ, Kandoth C, Welch J, Ma C, Wendl MC, Payne SH, Fenyö D, Townsend RR, Dipersio JF, Chen F, Ding L. Sengupta S, et al. Genome Med. 2018 Jul 27;10(1):60. doi: 10.1186/s13073-018-0564-z. Genome Med. 2018. PMID: 30053901 Free PMC article.
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model.
Karlsson J, Hagemann UB, Cruciani V, Schatz CA, Grant D, Ellingsen C, Kristian A, Katoozi S, Mihaylova D, Uran SR, Suominen M, Bjerke RM, Ryan OB, Cuthbertson A. Karlsson J, et al. Cancers (Basel). 2023 Jun 29;15(13):3419. doi: 10.3390/cancers15133419. Cancers (Basel). 2023. PMID: 37444529 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal